The abstract is read at the publisher; the summary is JClub's.
Batch size, not master stock size, governs the risk of cancer-like genetic variants during bioreactor expansion of human pluripotent stem cells (hPSCs) in scale-up versus scale-out simulations.
- Why it matters: Genetic variants can jeopardize bioreactor expansion for cell therapy manufacturing, but it is unclear which operational lever most affects variant emergence and detection.
- What they did: The authors simulated scale-up versus scale-out culture and compared how batch size and master stock size influence variant risk, including how scale-out compartmentalization affects detection timing and variant amplification.
- The result: Scale-out detects contamination sooner and lowers manufacturing cost when risk is factored, but it also amplifies rare variants relative to scale-up.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.